Evaluation of the Levels of bFGF, VEGF, sICAM-1, and sVCAM-1 in Serum of Patients with Thyroid Cancer

Pasieka, Zbigniew; Stępień, H; Komorowski, Jan; Kołomecki, Krzysztof; Kuzdak, Krzysztof

doi:10.1007/978-3-642-59349-9_18

Cited by 28 publications

(18 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, within areas of elevated VEGF concentration enhanced blood vessel growth/angiogenesis can be observed. In the context of pathological angiogenesis the higher vascularisation of inflammatory areas and the vascularisation of tumours (42) for their supply may be mentioned. The secretion of VEGF from osteoblasts treated with different abrasive wear particles suggests that wear debris may induce tumourigenesis in the periprosthetic region.…”

Section: Discussionmentioning

confidence: 99%

The potential role of human osteoblasts for periprosthetic osteolysis following exposure to wear particles

Lochner

2011

Int J Mol Med

103

View full text Add to dashboard Cite

Abstract. Aseptic loosening in total hip replacement is mainly caused by wear particles inducing inflammation and osteolysis. Wear can be a consequence of micromotions at the interface between implant and bone cement. Due to complex cellular interactions, different mediators (e.g. cytokines, proteinases) are released, which can promote osteolytic processes in the periprosthetic tissue followed by loosening of the implant. Furthermore, a reduced matrix synthesis and an induced apoptosis rate can be observed. The purpose of this study was to evaluate to what extent human primary osteoblasts exposed to wear particles are involved in the osteolysis. The viability, the secretion of collagen and collagenases and the variety of released cytokines after particle exposure was examined. Therefore, human osteoblasts were incubated with particles experimentally generated in the interface between hip stems with rough and smooth surface finishings as well as different material compositions (Ti-6Al-7Nb, Co-28Cr-6Mo and 316L) and bone cement mantle made of Palacos R containing zirconium oxide particles. Commercially pure titanium particles, titanium oxide, polymethylmethacrylate and particulate zirconium oxide were used as references. The results revealed distinct effects on the cytokine release of human osteoblasts towards particulate debris. Thereby, human osteoblasts released increased levels of interleukine (IL)-6 and IL-8 after treatment with metallic wear particles. The expression of VEGF was slightly induced by all particle entities at lower concentrations. Apoptotic rates were enhanced for osteoblasts exposed to all the tested particles. Furthermore, the de novo synthesis of type 1 collagen was reduced and the expression of the matrix metalloproteinase (MMP)-1 was considerably increased. However, wear particles of Co-28Cr-6Mo stems seemed to be more aggressive, whereas particles derived from stainless steel stems caused less adverse cellular reaction. Among the reference particles, which caused less altered reactions in the metabolism of osteoblasts in general, ZrO 2 can be assumed as the material with the smallest cell biological effects.

show abstract

Section: Discussionmentioning

confidence: 99%

The potential role of human osteoblasts for periprosthetic osteolysis following exposure to wear particles

Lochner

2011

Int J Mol Med

103

View full text Add to dashboard Cite

show abstract

“…Increased amounts of the mRNA and protein of growth factors like VEGF-A, PDGF-B and EGFR were found in thyroid tumor cells and PTC in vitro (36) as well as in vivo (37,38). Increased serum concentrations of VEGF-A and EGFR protein were also reported in PTC (36,39), eventually inducing systemic effects. It is interesting to note that increased levels were especially linked with PTC characterized by lymph node metastases and more aggressive behavior (40) and patients over the age of 45 (41).…”

Section: Figmentioning

confidence: 97%

A Radiation-Induced Gene Signature Distinguishes Post-Chernobyl from Sporadic Papillary Thyroid Cancers

Port

Boltze

Wang³

et al. 2007

Radiation Research

View full text Add to dashboard Cite

“…Serum VEGF is significantly elevated in patients with papillary thyroid cancer compared with the control group (43), especially in patients with metastatic differentiated thyroid cancer but not in those with poorly differentiated thyroid cancer metastases (44).…”

Section: Vegf Receptormentioning

confidence: 76%

New perspectives on the treatment of differentiated thyroid cancer

Coelho

Carvalho

2007

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Even though differentiated thyroid carcinoma is a slow growing and usually curable disease, recurrence occurs in 20-40% and cellular dedifferentiation in up to 5% of cases. Conventional chemotherapy and radiotherapy have just a modest effect on advanced thyroid cancer. Therefore, dedifferentiated thyroid cancer represents a therapeutic dilemma and a critical area of research. Targeted therapy, a new generation of anticancer treatment, is planned to interfere with a specific molecular target, typically a protein that is believed to have a critical role in tumor growth or progression. Since many of the tumor-initiation events have already been identified in thyroid carcinogenesis, targeted therapy is a promising therapeutic tool for advanced thyroid cancer. Several new drugs are currently being tested in in vitro and in vivo studies and some of them are already being used in clinical trials, like small molecule tyrosine kinase inhibitors. In this review, we discuss the bases of targeted therapies, the principal drugs already tested and also options of redifferentiation therapy for thyroid carcinoma. Apesar de o carcinoma diferenciado da tireóide ser considerado uma doença de curso indolente e geralmente curável, recorrência tumoral ocorre em aproximadamente 20 a 40% e desdiferenciação celular, em até 5% dos casos. A quimioterapia convencional e a radioterapia apresentam apenas um modesto efeito sobre o câncer de tireóide avançado. Dessa forma, o carcinoma da tireóide desdiferenciado representa um dilema terapêutico e uma importante área de pesquisa. A terapia direcionada, uma nova geração de tratamento para o câncer, tem como objetivo interferir com um alvo molecular específico, geralmente uma proteína considerada fundamental para o crescimento e progressão tumoral. Como muitos eventos iniciadores do processo de carcinogênese tireoideana já foram identificados, a terapia direcionada representa uma promissora opção terapêutica para o carcinoma da tireóide avançado. Várias drogas novas estão em estudos in vitro e in vivo e algumas já estão sendo testadas em estudos clínicos, como as pequenas moléculas inibidoras de tirosina cinase. Nesta revisão, as bases moleculares da terapia direcionada, as principais drogas utilizadas e as opções terapêuticas de rediferenciação do carcinoma da tireóide serão discutidas.

show abstract

Evaluation of the Levels of bFGF, VEGF, sICAM-1, and sVCAM-1 in Serum of Patients with Thyroid Cancer

Cited by 28 publications

References 24 publications

The potential role of human osteoblasts for periprosthetic osteolysis following exposure to wear particles

The potential role of human osteoblasts for periprosthetic osteolysis following exposure to wear particles

A Radiation-Induced Gene Signature Distinguishes Post-Chernobyl from Sporadic Papillary Thyroid Cancers

New perspectives on the treatment of differentiated thyroid cancer

Contact Info

Product

Resources

About